Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BYSI NASDAQ:FENC NASDAQ:HRTX NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBYSIBeyondSpring$1.44+1.4%$1.61$1.21▼$3.44$59.21M0.4123,546 shs1,814 shsFENCAdherex Technologies$7.19+4.2%$6.99$5.65▼$9.92$248.87M0.91153,212 shs30,773 shsHRTXHeron Therapeutics$1.24-0.4%$0.97$0.74▼$2.30$232.97M1.71.88 million shs428,502 shsVYGRVoyager Therapeutics$4.21+6.3%$4.04$2.64▼$5.55$254.66M1.26653,917 shs273,378 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBYSIBeyondSpring-8.39%-10.86%-17.44%-5.33%-16.47%FENCAdherex Technologies-3.90%+6.32%+9.18%-11.99%+12.93%HRTXHeron Therapeutics-5.34%+3.33%+57.08%-1.59%-45.01%VYGRVoyager Therapeutics-5.04%+6.17%0.00%+7.61%+20.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBYSIBeyondSpring$1.44+1.4%$1.61$1.21▼$3.44$59.21M0.4123,546 shs1,814 shsFENCAdherex Technologies$7.19+4.2%$6.99$5.65▼$9.92$248.87M0.91153,212 shs30,773 shsHRTXHeron Therapeutics$1.24-0.4%$0.97$0.74▼$2.30$232.97M1.71.88 million shs428,502 shsVYGRVoyager Therapeutics$4.21+6.3%$4.04$2.64▼$5.55$254.66M1.26653,917 shs273,378 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBYSIBeyondSpring-8.39%-10.86%-17.44%-5.33%-16.47%FENCAdherex Technologies-3.90%+6.32%+9.18%-11.99%+12.93%HRTXHeron Therapeutics-5.34%+3.33%+57.08%-1.59%-45.01%VYGRVoyager Therapeutics-5.04%+6.17%0.00%+7.61%+20.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBYSIBeyondSpring 1.00SellN/AN/AFENCAdherex Technologies 2.57Moderate Buy$14.80105.81% UpsideHRTXHeron Therapeutics 2.20Hold$4.50264.37% UpsideVYGRVoyager Therapeutics 2.75Moderate Buy$16.50291.92% UpsideCurrent Analyst Ratings BreakdownLatest BYSI, VYGR, FENC, and HRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026FENCAdherex Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026HRTXHeron Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/16/2026FENCAdherex Technologies WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$13.004/15/2026VYGRVoyager Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026BYSIBeyondSpring Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)3/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/25/2026FENCAdherex Technologies Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/25/2026VYGRVoyager Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/17/2026VYGRVoyager Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.002/26/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBYSIBeyondSpringN/AN/A$0.11 per share13.64($0.59) per shareN/AFENCAdherex Technologies$44.64M5.56N/AN/A$1.04 per share6.91HRTXHeron Therapeutics$154.90M1.50N/AN/A$0.07 per share17.64VYGRVoyager Therapeutics$40.37M6.30N/AN/A$3.53 per share1.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBYSIBeyondSpring-$1.01M-$0.15N/AN/AN/AN/AN/A-12.39%5/12/2026 (Estimated)FENCAdherex Technologies-$9.74M-$0.34N/A8.46N/A-22.62%-183.18%-15.31%5/12/2026 (Estimated)HRTXHeron Therapeutics-$20.19M-$0.13N/A10.29N/A-13.04%N/A-4.62%5/11/2026 (Estimated)VYGRVoyager Therapeutics-$119.72M-$2.03N/AN/AN/A-296.53%-51.35%-39.38%5/11/2026 (Estimated)Latest BYSI, VYGR, FENC, and HRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q4 2025BYSIBeyondSpring-$0.54N/AN/AN/A$8.77 millionN/A5/12/2026Q1 2026FENCAdherex Technologies-$0.02N/AN/AN/A$13.78 millionN/A5/11/2026Q1 2026HRTXHeron Therapeutics-$0.03N/AN/AN/A$36.72 millionN/A5/11/2026Q1 2026VYGRVoyager Therapeutics-$0.54-$0.47+$0.07-$0.47$8.79 million$1.19 million3/25/2026Q4 2025BYSIBeyondSpring-$0.54-$0.05+$0.49-$0.05N/AN/A3/24/2026Q4 2025FENCAdherex Technologies$0.0423-$0.17-$0.2123-$0.17$14.75 million$13.78 million3/24/2026Q4 2025FENCAdherex Technologies$0.03-$0.17-$0.20-$0.17$14.73 million$13.78 million3/9/2026Q4 2025VYGRVoyager Therapeutics-$0.54-$0.46+$0.08-$0.46$10.49 million$13.46 million2/26/2026Q4 2025HRTXHeron Therapeutics-$0.03-$0.02+$0.01-$0.02$39.53 million$40.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBYSIBeyondSpringN/AN/AN/AN/AN/AFENCAdherex TechnologiesN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBYSIBeyondSpringN/A1.541.54FENCAdherex TechnologiesN/A6.376.23HRTXHeron Therapeutics10.592.481.51VYGRVoyager TherapeuticsN/A7.647.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBYSIBeyondSpring40.29%FENCAdherex Technologies55.51%HRTXHeron Therapeutics80.01%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipBYSIBeyondSpring29.31%FENCAdherex Technologies11.76%HRTXHeron Therapeutics5.86%VYGRVoyager Therapeutics6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBYSIBeyondSpring8041.12 million29.07 millionOptionableFENCAdherex Technologies1034.54 million30.48 millionOptionableHRTXHeron Therapeutics300188.64 million177.59 millionOptionableVYGRVoyager Therapeutics10060.42 million56.56 millionOptionableBYSI, VYGR, FENC, and HRTX HeadlinesRecent News About These CompaniesVoyager Therapeutics (NASDAQ:VYGR) Announces Quarterly Earnings ResultsMay 7 at 10:16 PM | marketbeat.comVoyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue EstimatesMay 7 at 7:01 PM | zacks.comVoyager Reports First Quarter 2026 Financial and Operating ResultsMay 7 at 4:01 PM | globenewswire.comVoyager Therapeutics (VYGR) to Release Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comH.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)May 1, 2026 | theglobeandmail.comVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s DiseaseApril 28, 2026 | markets.businessinsider.comVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's DiseaseApril 27, 2026 | globenewswire.comVoyager Therapeutics (NASDAQ:VYGR) Share Price Crosses Above Fifty Day Moving Average - Here's WhyApril 22, 2026 | marketbeat.comVoyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026April 13, 2026 | seekingalpha.comAlfred Sandrock Sells 11,511 Shares of Voyager Therapeutics (NASDAQ:VYGR) StockApril 4, 2026 | insidertrades.comVoyager Therapeutics (VYGR) price target increased by 12.22% to 17.17March 27, 2026 | msn.comVoyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum TranscriptMarch 23, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)March 19, 2026 | theglobeandmail.comGuggenheim Remains a Buy on Voyager Therapeutics (VYGR)March 13, 2026 | theglobeandmail.comDoes Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline?March 12, 2026 | finance.yahoo.comVoyager Therapeutics: Q4 Earnings SnapshotMarch 10, 2026 | finance.yahoo.comVoyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue EstimatesMarch 9, 2026 | zacks.comVoyager Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsMarch 9, 2026 | globenewswire.comVoyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference TranscriptMarch 3, 2026 | seekingalpha.comTodd Alfred Carter Sells 4,174 Shares of Voyager Therapeutics (NASDAQ:VYGR) StockFebruary 27, 2026 | insidertrades.comVoyager Therapeutics Announces Chief Medical Officer ResignationFebruary 19, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBYSI, VYGR, FENC, and HRTX Company DescriptionsBeyondSpring NASDAQ:BYSI$1.44 +0.02 (+1.41%) As of 11:24 AM Eastern This is a fair market value price provided by Massive. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Adherex Technologies NASDAQ:FENC$7.19 +0.29 (+4.22%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Heron Therapeutics NASDAQ:HRTX$1.24 -0.01 (-0.40%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Voyager Therapeutics NASDAQ:VYGR$4.21 +0.25 (+6.31%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
